PharmaCyte Biotech Reports $5.08 Million Net Loss for Quarter Ended July 31, 2026

PharmaCyte Biotech, Inc. reported its financial results for the three months ended July 31, 2026, revealing a net loss of $5.08 million, or $0.54 per share, compared to a net loss of $8.36 million, or $1.23 per share, for the same period in 2025. The company did not generate any revenue during this quarter, consistent with the previous year. Operating expenses totaled $1.01 million, which included $946,708 in general and administrative costs and $60,000 in research and development expenses. The latter reflects a decrease from $95,157 in the prior year, attributed to renegotiated consultant terms.

The company’s total assets decreased to $36.71 million as of July 31, 2026, down from $46.75 million at the end of the previous fiscal period. This decline was primarily due to reductions in cash and cash equivalents, which fell to $17.74 million from $18.60 million. The decrease in total assets was also influenced by a significant drop in the fair value of investments, particularly in Q/C Technologies, Inc., where the fair value of preferred stock decreased from $18.23 million to $12.68 million. The company’s liabilities also decreased, totaling $6.90 million compared to $11.77 million in the prior period.

Strategically, PharmaCyte has been focused on addressing a clinical hold placed by the U.S. Food and Drug Administration (FDA) on its Investigational New Drug Application (IND) for a planned clinical trial in locally advanced pancreatic cancer (LAPC). The company has been conducting additional preclinical studies and gathering required information to lift the hold. A Business Review Committee has been formed to evaluate the company’s operations and its relationship with SG Austria, which has led to a curtailment of spending on development programs until a new framework is established.

As of the reporting date, PharmaCyte had 10,735,649 shares of common stock outstanding. The company is classified as a smaller reporting company and has indicated that it expects its current cash reserves will be sufficient to meet its operational needs for at least the next twelve months. However, it anticipates needing additional capital to complete its clinical trial for LAPC, which may involve dilutive equity financing or restrictive debt financing. The company is actively exploring options to secure funding while navigating the complexities of regulatory compliance and market conditions.

Looking ahead, PharmaCyte remains focused on advancing its Cell-in-a-Box® technology and addressing the FDA's requirements to lift the clinical hold. The company is also considering alternative approaches to expand its prodrug/activator technology for cancer treatment. The ongoing evaluation of its business strategy and operational framework is expected to influence its future development activities and financial performance.